SCHEMBL4836853

SCHEMBL4836853

O=CC1(N2CCc3ccccc3C2CCN2CCC(c3ccc(Cl)cc3)CC2)CCCCCC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
MCHR1 Q99705 4/20 0.40
HTR1A P08908 3/20 0.40
HTR7 P34969 2/20 0.40
HTR2A P28223 1/20 0.40
HTR6 P50406 1/20 0.40
ADRB2 P07550 1/20 0.39
ADRA2A P08913 1/20 0.39
CX3CR1 P49238 1/20 0.39
DRD3 P35462 1/20 0.38
KCNH2 Q12809 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ADRA1B P35368 2/20 0.37
PRCP P42785 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839168 0.99 DRD2 (0.42) DRD2SIGMAR1MCHR1HTR1AHTR7
SCHEMBL4839410 0.81 CCR3 (0.43) DRD2SIGMAR1HTR1AADRB2DRD3
SCHEMBL4835931 0.80 OPRM1 (0.49) HTR1AHTR7HTR2AHTR6KCNH2
SCHEMBL4838819 0.77 NPSR1 (0.53) DRD2MCHR1MEN1KMT2A
SCHEMBL4836850 0.77 NPSR1 (0.53) DRD2MCHR1MEN1KMT2A
SCHEMBL4839157 0.76 ALDH1A1 (0.52) DRD2MCHR1MEN1KMT2APRCP
SCHEMBL4839404 0.74 MCHR1 (0.46) DRD2MCHR1MEN1KMT2APRCP
SCHEMBL4838758 0.72 MCHR1 (0.46) DRD2MCHR1DRD3MEN1KMT2A
SCHEMBL4841563 0.72 DRD2 (0.54) DRD2MCHR1HTR1AHTR2ADRD3
SCHEMBL4841467 0.71 MCHR1 (0.46) DRD2MCHR1HTR1AHTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 DRD2 684/4885SIGMAR1 1345/4885MCHR1 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.